SEOUL - The stem cell and gene therapy market is forecast to grow rapidly with large pharma firms beginning to pay strong attention to the sector, although the industry still needs to overcome challenges such as tough regulations, high prices of therapies, lack of target patients and worries over safety and efficacy of the drugs.
The era of third generation biomedicines including gene and cell therapies appears to have started, with R&D activities in this sector in South Korea and more broadly becoming active in recent years, although some experts are still skeptical as to whether the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?